Cargando…

New hepatitis C therapies in clinical development

With the current standard of care for the treatment of chronic hepatitis C, a combination of pegylated interferon alfa and ribavirin, sustained virologic response rates can be achieved in approximately 50% of patients only. Improved understanding of the viral life cycle has led to the identification...

Descripción completa

Detalles Bibliográficos
Autores principales: Vermehren, Johannes, Sarrazin, Christoph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3352002/
https://www.ncbi.nlm.nih.gov/pubmed/21813371
http://dx.doi.org/10.1186/2047-783X-16-7-303
_version_ 1782232827167768576
author Vermehren, Johannes
Sarrazin, Christoph
author_facet Vermehren, Johannes
Sarrazin, Christoph
author_sort Vermehren, Johannes
collection PubMed
description With the current standard of care for the treatment of chronic hepatitis C, a combination of pegylated interferon alfa and ribavirin, sustained virologic response rates can be achieved in approximately 50% of patients only. Improved understanding of the viral life cycle has led to the identification of numerous potential targets for novel, direct-acting antiviral compounds. Inhibitors of the NS3/4A protease are currently the most advanced in clinical development. Recently completed phase 3 studies of the two protease inhibitors telaprevir and boceprevir, each given in combination with standard of care, yielded sustained virologic response rates in the range of 66-75% in treatment-naive patients and 59-66% in treatment-experienced patients with HCV genotype 1 infection. Studies of second-generation protease inhibitors, with the potential advantage of improved potency, drug metabolism and pharmacokinetics profile, are already underway. Inhibitors of the HCV NS5A protein and NS5B polymerase are potentially active across different HCV genotypes and have shown promising antiviral efficacy in early clinical studies. Other emerging mechanisms include silymarin components and inhibitors of cell proteins required for HCV replication. While improved formulations of current HCV therapies are also being developed, future hopes lie on the combination of direct-acting antivirals with the eventual possibility of interferon-free treatment regimens.
format Online
Article
Text
id pubmed-3352002
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-33520022012-05-16 New hepatitis C therapies in clinical development Vermehren, Johannes Sarrazin, Christoph Eur J Med Res Review With the current standard of care for the treatment of chronic hepatitis C, a combination of pegylated interferon alfa and ribavirin, sustained virologic response rates can be achieved in approximately 50% of patients only. Improved understanding of the viral life cycle has led to the identification of numerous potential targets for novel, direct-acting antiviral compounds. Inhibitors of the NS3/4A protease are currently the most advanced in clinical development. Recently completed phase 3 studies of the two protease inhibitors telaprevir and boceprevir, each given in combination with standard of care, yielded sustained virologic response rates in the range of 66-75% in treatment-naive patients and 59-66% in treatment-experienced patients with HCV genotype 1 infection. Studies of second-generation protease inhibitors, with the potential advantage of improved potency, drug metabolism and pharmacokinetics profile, are already underway. Inhibitors of the HCV NS5A protein and NS5B polymerase are potentially active across different HCV genotypes and have shown promising antiviral efficacy in early clinical studies. Other emerging mechanisms include silymarin components and inhibitors of cell proteins required for HCV replication. While improved formulations of current HCV therapies are also being developed, future hopes lie on the combination of direct-acting antivirals with the eventual possibility of interferon-free treatment regimens. BioMed Central 2011-07-25 /pmc/articles/PMC3352002/ /pubmed/21813371 http://dx.doi.org/10.1186/2047-783X-16-7-303 Text en Copyright ©2011 I. Holzapfel Publishers
spellingShingle Review
Vermehren, Johannes
Sarrazin, Christoph
New hepatitis C therapies in clinical development
title New hepatitis C therapies in clinical development
title_full New hepatitis C therapies in clinical development
title_fullStr New hepatitis C therapies in clinical development
title_full_unstemmed New hepatitis C therapies in clinical development
title_short New hepatitis C therapies in clinical development
title_sort new hepatitis c therapies in clinical development
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3352002/
https://www.ncbi.nlm.nih.gov/pubmed/21813371
http://dx.doi.org/10.1186/2047-783X-16-7-303
work_keys_str_mv AT vermehrenjohannes newhepatitisctherapiesinclinicaldevelopment
AT sarrazinchristoph newhepatitisctherapiesinclinicaldevelopment